Endo International PLC

Most Recent

  • uploads///holdings in valeant
    Company & Industry Overviews

    What Does Valeant’s Institutional Ownership Look Like?

    Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.

    By Jillian Dabney
  • uploads///ICE presso
    Consumer

    Why did Lone Pine open a position in IntercontinentalExchange?

    Lone Pine Capital opened a new 2.19% position in IntercontinentalExchange Group, Inc.

    By Samantha Nielson
  • uploads///segemnts and margins
    Company & Industry Overviews

    Yes, There Will Be Margin Erosion for Valeant in 2017

    Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.

    By Jillian Dabney
  • uploads///pulse trace _
    Company & Industry Overviews

    Analyst Ratings for Endo International and Peers in August

    In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.

    By Margaret Patrick
  • uploads///SBAC
    Consumer

    Why did Lone Pine Capital buy a stake in SBA Communications?

    SBA Communications Corporation is a 2.11% position initiated by Lone Pine Capital in 4Q 2013.

    By Samantha Nielson
  • uploads///revenue ee
    Earnings Report

    How Did Valeant Fare in 2Q16?

    Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.

    By Jillian Dabney
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Recommend for Valeant after Recent Happenings

    The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.

    By Jillian Dabney
  • uploads///generics
    Earnings Report

    Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016

    Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.

    By Jillian Dabney
  • uploads///VRX
    Fund Managers

    Point72 Reduces Its Stake in Valeant Pharmaceuticals

    Point72 reduced its stake in Valeant Pharmaceuticals by selling 924,400 shares. It held 132,300 Valeant shares. Valeant accounted for 0.13% of the fund’s 4Q14 portfolio.

    By Diana Key
  • uploads///ENDP
    Fund Managers

    Glenview Capital raises position in Endo International

    Glenview Capital Management added to its position in Endo International Plc (ENDP) in the third quarter. Currently, the position accounts for 2.02% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///SHPG
    Fund Managers

    Shire Gets Dropped from AQR Capital’s Portfolio

    During the fourth quarter of 2014, AQR Capital closed its position in Shire plc (SHPG). The fund sold its entire stake of 816,116 shares in the company.

    By Stuart McKenzie
  • uploads///laboratory _
    Company & Industry Overviews

    What Are Analysts Recommending for TEVA and ENDP in May?

    On May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close.

    By Margaret Patrick
  • uploads///human skeleton _
    Company & Industry Overviews

    Analysts’ Views on Endo International and Mallinckrodt

    Most analysts covering Endo International (ENDP) and Mallinckrodt (MNK) recommend “hold.” On March 5, Endo closed at $8.72, and Mallinckrodt closed at $22.39.

    By Margaret Patrick
  • uploads///anr
    Company & Industry Overviews

    What Are Analysts Saying about Horizon Pharma?

    According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”

    By Jillian Dabney
  • uploads///operating segments
    Earnings Report

    How Did Mallinckrodt’s Specialty Brands Perform in 2016?

    Specialty Brands had a 69% in Mallinckrodt’s total revenue in 2016, while Specialty Generics had a 31% share.

    By Jillian Dabney
  • uploads///revenue
    Earnings Report

    Mallinckrodt’s Revenue Growth in Fiscal 4Q16

    On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Teva Leads the Industry in First-to-File Applications in 2016

    Teva Pharmaceutical (TEVA) is the leading generic pharmaceutical company in terms of first-to-file (or FTF) applications in the United States.

    By Margaret Patrick
  • uploads///seven point health plan
    Macroeconomic Analysis

    What Is Donald Trump’s Seven-Point Health Plan?

    Trump’s healthcare agenda During his campaign, Trump came up with a seven-point plan for the healthcare industry. In this plan, he proposed to repeal the Affordable Care Act. Although a complete repeal doesn’t seem feasible, if applied, it would definitely take a toll on hospitals and insurance companies. In the next article, we’ll discuss the severity of […]

    By Jillian Dabney
  • uploads///salix portfolio
    Company & Industry Overviews

    Valeant’s Salix Acquisition Saga

    Valeant won the acquisition race for Salix by valuing it at $14.5 billion, inclusive of net debt. In April 2015, Valeant paid $158 per Salix share.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Valeant Looks to Boost Profit Margins through the Walgreens Deal

    On December 15, 2015, Valeant Pharmaceuticals (VRX) announced its decision to enter into a fulfillment agreement with Walgreens.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Research Pipeline and Generic Product Launches in 2016

    The combined Teva Pharmaceutical–Allergan Generics company filed 65 ANDAs (Abbreviated New Drug Applications) in 2015.

    By Margaret Patrick
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///US High Yield Bond Fund Flows
    Company & Industry Overviews

    High-Yield Bond Funds See Miniscule Inflows in Week Ended July 8

    Net inflows into high-yield bond funds totaled $45.1 million in the week ended July 8. It was the smallest inflow so far this year. High-yield bond funds have seen inflows of $280 million year-to-date.

    By David Ashworth
  • uploads///ENDP_BBG
    Fund Managers

    Endo International, a New Position for OZ Management

    In 4Q14, Oz Management added a new stake in Endo International plc (ENDP) by purchasing 5,221,710 shares, representing 1.01% of the fund’s 4Q14 portfolio.

    By Stuart McKenzie
  • uploads///PCLN
    Fund Managers

    Priceline Group loses its position in Chilton Investment Company

    Chilton Investment Company exited its position in Priceline Group Inc. (PCLN), which accounted for 1.19% of the fund’s 3Q14 portfolio.

    By Adam Rogers
  • uploads///DOW
    Fund Managers

    Soros continues to be bullish on Dow Chemical

    Soros Fund Management upped its position in Dow Chemical (DOW) in the fourth quarter. The position now accounts for 2.58% of the fund’s 4Q14 portfolio.

    By Samantha Nielson
  • uploads///LYB
    Fund Managers

    LyondellBasell is a brand new position in Soros’ 4Q portfolio

    Netherlands-based LyondellBasell, which came out of chapter 11 bankruptcy in 2010, is one of the world’s top five independent chemical companies based on revenues.

    By Samantha Nielson
  • uploads///NEE
    Basic Materials

    Millennium Management increases its stake in NextEra Energy

    Millennium Management increased its stake in renewable energy generator NextEra Energy Inc. (NEE) from 1,789,954 shares to 3,333,627 shares.

    By Samantha Nielson
  • uploads///PRGO
    Basic Materials

    Israel Englander’s Millennium Management ups its stake in Perrigo

    Millennium Management ups position in Perrigo Company PLC (PRGO) that currently accounts for 1.28% of the fund’s 4Q portfolio.

    By Samantha Nielson
  • uploads///STI
    Basic Materials

    Millennium Management buys a new position in SunTrust Banks

    Millennium Management started a new position in SunTrust Banks (STI) that accounts for 0.15% of the fund’s portfolio.

    By Samantha Nielson
  • uploads///EQIX
    Consumer

    Why did Lone Pine Capital decide to move out of Equinix?

    Lone Pine Capital exited a 1.78% position in Equinix, Inc. in 4Q 2013.

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.